UZ GENT

Gent 10 trials 5 recruiting

10 Registered trials

5 Currently recruiting

Organisation

UZ GENT

Location

Gent, Belgium

Identifier

ORL-000002225

Address

Corneel Heymanslaan 10, 9000, Belgium

Departments

Department of Hematology
Gastroenterology
Hematology
Neurology
Oncology
Paediatric Haemato-oncology
Paediatric Neurology
Pediatric Hematology - Oncology

Clinical trials at this site (10)

Search interface

PTX3 genetically stratified randomized double-blinded allocation event-driven clinical trial for antifungal prophylaxis in patients with acu… Pending

2024-517211-79-00 Antifungal prophylaxis in patients with acute myeloid l 6
ASPIRING Recruiting

2024-516188-10-00 Intracerebral haemorrhage 6 2025-10-07
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic … Recruiting

2025-522860-34-00 Chronic lymphocytic leukemia (CLL) 5 2025-12-16
A Study to Evaluate Whether Healing all Bowel Wall Layers is a Superior Treatment Target in Patients with Active Crohn’s Disease (CD). Recruiting

2023-509096-16-00 Moderately to Severely Active Crohn’s Disease 6 2024-07-31
C1071032 - MAGNETISMM-32 A PHASE 3, OPEN-LABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMB, POMALIDOMIDE, DEXAMETHASONE (EPd) OR POMAL… Recruiting

2023-507871-23-00 Relapsed/Refractory Multiple Myeloma 5 2024-05-27
International proof of concept therapeutic Stratification trial of Molecular Anomalies in Relapsed or Refractory HEMatological malignancies … Recruiting

2022-501869-41-00 Acute Lymphoblastic Leukemia, in Relapse Lymphoblastic 9 2023-11-14
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study Ended

2023-507418-28-00 Solid tumors 4 2021-03-15
LUCENT-3 Extension Study of Mirikizumab in Ulcerative Colitis Ended

2023-507657-15-00 Ulcerative Colitis 5 2018-09-13
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine (PIONEER-PEDS2) Ended

2023-506724-85-00 Migraine 5 2020-11-19
Efficacy and safety of tisotumab vedotin (HuMax®-TF-ADC) monotherapy and in combination in recurrent or Stage IVB cervical cancer Ended

2023-508832-68-00 Recurrent or stage IVB cervical cancer 9 2019-03-28